Personalized Regenerative Medicine

I am continuing to get results: For 8 months I could not stress my left knee with squats or leg presses. The last 2 days (5 & 6th day on Stemgevity) I said what the hell, my knee feels so go good, I will give it a shot and do some one legged presses with my previously damaged knee (it has been 8 months and it just would not take that kind of stress).

So, for the last 2 days in a row I have been doing them with heavy weight. Unbelievable -completely pain-free during and after, and no soreness the next day. Just incredible. I have been taking every exotic natural product under the sun to heal it and the Stemgevity did it, made it happen. It is completely well playing racquet ball with full stress on it and no problems no soreness and no pain. My energy levels are way up and you feel kind of a glow. I can work long hard days at age 65 and at the end of the day, I still feel great. I might as well be 20. This is perfect as our business is intense (selling bank repo homes at high volume) and I simply have to keep up. Also, I had bad strep throat and a chronic knee and shoulder -and yes, the shoulder is now pain free and no longer tight after playing intense racquetball. Again, amazing.

View post:
Personalized Regenerative Medicine

Stem Cell Doctors Delaware, Stem cell injections, Stem cell …

Stem cells are a particular sort of cells that have the capacity to repeat and recover themselves inside the human body. Grown-up mesenchymal foundational microorganisms work as a sort of interior repair framework, having the capacity to separate to recharge different cells. These regenerative cells have the one of a kind ability to remain an undifferentiated cell or turn into another sort of cell with a particular capacity inside the human body, for example, bone, ligament, muscle or skin cells. Given their great and extraordinary regenerative nature, fat inferred regenerative cell treatment offers new potential in the treatment of specific signs.

Delaware, USA a small Mid-Atlantic U.S. state, sits on a peninsula marked by dune-backed beaches bordering the Atlantic Ocean, Delaware River and Delaware Bay. In Dover, the capital, First State Heritage Park encompasses 18th-century Colonial landmarks like the Georgian-style Old State House.

Stem cells have the capability to modify into specific cell types. There are two defining characteristics of a stem cell are perpetual self-renewal and the ability to differentiate into a specialized adult cell type.

We offer a complete way to deal with construct their training by teaching people in general in a straightforward way. Our careful screening process insures doctors a high quality treatment for patients suffering from inflammatory and degenerative conditions.

For further information about our systems or doctors Contact us today.

Read the original:
Stem Cell Doctors Delaware, Stem cell injections, Stem cell ...

Stem Cell Transplantation and Cellular Therapy Center | MD …

MDAnderson's Stem Cell Transplantation and Cellular Therapy Center is one of the largest facilities in the world for stem cell transplants. During stem cell transplants, unhealthy bone marrow is replaced by healthy stem cells. These stem cells then develop into healthy marrow that produces different types of blood cells.

We perform more than 850 procedures for adults and children each year, more than any other center in the nation. The cancers, hematologic diseases and autoimmune disorders we treat include:

As part of one the nations top cancer centers, we provide comprehensive stem cell transplant services. These include a clinic dedicated to monitoring and managing graft versus host disease, a condition that can arise from stem cell transplantation; and a matched unrelated donor program, which has earned us recognition as a specialized center for stem cell transplants by the National Marrow Donor Program.

We also maintain our own cell processing laboratory for preparing safe and effective tissues for transplantation and perform more than more than1,000 collections each year through our apheresis and stem cell collection unit.

Link:
Stem Cell Transplantation and Cellular Therapy Center | MD ...

A Rare Side Effects of Stem Cell Therapy: A Case Study

By: Ian Murnaghan BSc (hons), MSc - Updated: 28 Sep 2018 | *Discuss

There is no doubt that stem cell therapy holds enormous potential. Unfortunately, this potential also brings with it side-effects, some particularly severe. Such was the case during a therapy that used human foetal stem cells.

The boy in the case suffered from a rare genetic disease known as Ataxia Telangiectasia. This disorder affects many areas of the body and can cause significant disability. The body does not coordinate properly and those who suffer from the disease have a weak immune system as well as problems with their respiratory system.

While there have been some cases reported where experimentation on rodents resulted in the growth of tumours after stem cell injection, this hadn't been documented in humans after foetal stem cell therapy. Researchers also knew that this risk in rodents could be reduced if the stem cells were differentiated before they were injected. This means that the stem cells were coaxed into the desired body cell for the therapy prior to injection.

In a person who has a healthy immune system, the normal 'checks' on the body would be more likely to prevent a tumour from establishing itself. We have known for some time now that there is the potential for stem cells to trigger the growths of tumours but the reality has been that this is a rarity.

Rather than put a stop to stem cell research, it has been suggested that we need to spend more time looking at the Safety of Stem Cells. We should try to find out more about what can potentially go wrong and then develop safeguards to reduce any risks associated with stem cell therapies. This way, we can get the most benefits from stem cells while minimising any chances of side-effects along the way.

You might also like...

Share Your Story, Join the Discussion or Seek Advice..

Kirsten - 28-Sep-18 @ 9:26 PM

Chiso - 20-Sep-18 @ 6:23 AM

aileen - 13-Sep-18 @ 8:26 AM

Daniel Nociaro - 28-Aug-18 @ 4:07 AM

Rey - 25-Aug-18 @ 8:15 AM

Mary - 8-Jul-18 @ 11:30 PM

Mary - 8-Jul-18 @ 2:41 PM

Mary - 8-Jul-18 @ 6:23 AM

kay - 7-Jul-18 @ 7:20 AM

Jare - 30-Jun-18 @ 4:03 PM

Julz - 26-Jun-18 @ 4:22 PM

andy - 26-Jun-18 @ 5:08 AM

Lucky - 23-Jun-18 @ 6:40 AM

Julie - 26-May-18 @ 10:10 PM

mickey - 16-May-18 @ 2:37 PM

Lucky - 10-May-18 @ 7:04 AM

mac - 25-Apr-18 @ 10:33 PM

mac - 25-Apr-18 @ 10:29 PM

Diwaprinters - 5-Apr-18 @ 9:34 AM

Engr - 23-Feb-18 @ 7:28 AM

Amjad - 31-Jan-18 @ 9:08 AM

aunt - 3-Nov-17 @ 11:35 AM

Babu - 24-Oct-17 @ 4:21 PM

Jules - 9-Sep-17 @ 8:29 AM

Hut - 24-Aug-17 @ 11:08 AM

anwar - 21-Jul-17 @ 10:04 AM

Som - 14-Jul-17 @ 4:06 PM

Dhiraj - 10-Jul-17 @ 11:18 AM

Harish - 25-Jun-17 @ 8:03 AM

jacky - 18-May-17 @ 10:06 PM

Title:

(never shown)

Continued here:
A Rare Side Effects of Stem Cell Therapy: A Case Study

Interstellar Trade – Atomic Rockets

(ed note: This is talking about sea-going trade in the 1600s, but it can be applied to a science fictional universe. Isaac Kuo says "When the rocket equation applied to the crew")

Gemelli Careri, an Italian adventurer, circled the world in the late 17th century. No part of his journey was more dangerous than the trip from Manila to Acapulco, made in 1697 on one of the deep-drafted, many-sailed boats known as the Manila Galleons. These trading ships spent more than two centuries delivering spices and luxury goods from Asia to the New World and Europe, earning enormous profits for their financiers, mostly Spanish colonists in Manila. But here is Careris description from Giro del Mondo (1699) of what life was like for their sailors:

There is Hunger, Thirst, Sickness, Cold, continual Watching, and other Sufferings [The sailors] endure all the plagues God sent upon Pharaoh to soften his hard heart; the Ship swarms with little Vermine, the Spaniards call Gorgojos, bred in the Bisket if Moses miraculously converted his Rod into a Serpent, aboard the Galeon a piece of Flesh, without any Miracle is converted into Wood, and in the shape of a Serpent.

The journey was interminable, the sea was unruly, the food infested. Abundance of poor Sailors fell Sick, Careri writes. As a paying passenger, he would have had slightly better conditions than most of the crew. But status didnt provide much safety: by the end of his journey, two officers, one pilots mate and the Captain Commander were buried at sea, their bodies dragged down by earthen jars tied around their ankles.

The captain died of a disease known as Berben, which according to Careri swells the Body, and makes the Patient dye talking. The second disease, and the most dangerous to the galleons sailors, is called the Dutch Disease, which makes the Mouth sore, putrefies the Gums, and makes the Teeth drop out. This one is more familiar we know it as scurvy. For most of its two and a half centuries in operation, the galleons sailors died in droves of these and other heinous maladies, teeth rattling from their heads, boils blooming on their limbs like black flowers.

The Berkeley historian Jan DeVries found that some 2 million Europeans made trading voyages to Asia between 1580 and 1795. Of these, only 920,412 survived: an overall mortality rate of 54 per cent. European companies, DeVries concludes, sacrificed one human life for every 4.7 tons of Asian cargo returned to Europe. Of course, the Europeans spread their diseases when they travelled, and made liberal use of violence, so the suffering of the people they discovered was even more awful than their own. But no less than colonialism itself, the unrelenting horrors of these sailors lives helped forge the world we live in.

The first Manila Galleon made the round trip between Acapulco and Manila in 1565, and then did it nearly every year until 1815. It was the last link connecting the Earths human populations. As soon as the Spanish arrive in Manila, says Arturo Girldez, professor of Spanish literature at the University of the Pacific in California, we have a permanent connection between all the landmasses.

Though much of the history of European exploration is told through fantastic tales of overland quests for cities of gold, the galleons, their owners and their crews had no more mythical or lofty goals than Maersk or other giant merchant shipping concerns do today. It was the seaborne quest for trade that bound the far reaches of the globe together, and it is trade that has kept the world connected.

Foremost among the objects of trade were spices. After being introduced to benighted Europe from the Middle East during the Crusades, Asian spices became spectacularly prized for both their taste and their purported medical benefits. For decades, the most desired spices, including nutmeg and clove, were grown only on tiny Pacific islands called the Moluccas. They came to Europe through complex overland chains of Asian and Arab middlemen, who each took exorbitant premiums.

Europeans soon realised that they had the means to cut out those middlemen: spectacularly advanced maritime technology. Trade in the Mediterranean had relied since antiquity on slow-moving galleys, driven by oars, hard to steer, and with shallow drafts that made them unfit for the open ocean. But advances starting in the seventh century had deepened keels, multiplied sails, and made rudders sturdier. This new breed of ship, which would become the backbone of the galleon trade, was fast and manoeuvrable, able to withstand stormy seas while carrying huge amounts of cargo and large cast guns.

Leveraging this new technology, the Portuguese reached the spice islands of Southeast Asia by sailing around Africa in the 15th century. The 1494 Treaty of Tordesillas prevented the worlds other then-great power, Spain, from taking the same route so they started searching for a westward path, by way of the New World.

The first to confront the task was Ferdinand Magellan, one of the explorers least due the reverence granted by grade-school history lessons. Magellans Spanish fleet (he himself was Portuguese, real name Ferno de Magalhes) left Seville in 1519, rounding the tip of South America and crossing to Asia in 99 days. Even that brief journey was more than Magellan had prepared for: by the time the fleet reached Guam, his sailors were gnawing on the leather fittings of their sails out of hunger.

Worse, Magellan didnt know how to sail back to Mexico. Todays carbon-fuelled ships can largely ignore the forces swirling around them, and simply follow the straightest possible line to their destination. But in the age of sail, wind and currents were a ships fuel. Corralled by the great forces of lunar gravitation, climate, and the Earths rotation, the oceans travel great looping paths that remain steady for centuries. These were the highways of European exploration and trade. While Magellan had known where to find the westward current to Asia, he didnt know the way back.

On 27 April 1521, Magellan got himself killed in a local conflict in the Philippines, and his fleet fell apart. His ship, the Trinidad, attempted to sail back across the Pacific the way it had come. It spent months being pushed back to Asia the naval equivalent of trying to climb up the down escalator before the crew finally surrendered in despair to local Portuguese forces. The second ship, the Victoria, took an existing westward route home, rounding Africa and returning to Spain in September 1522, completing the first full circumnavigation of the Earth.

It was a historic milestone, but no model for a profitable trade route. For that, the Spanish needed to find the return route from Manila to Mexico, the eastward leg of the Pacific Gyre. They spent decades searching for it, before finally succeeding thanks to the sailor-monk Andrs de Urdaneta. A different breed altogether from Magellan, and far more deserving of memorialisation, Urdaneta was thoughtful and devout. He had stayed for 9 years on the Moluccas after an ill-fated 1525 Spanish expedition, so he knew the region well. He was 66 and a man of the cloth in Mexico City when, in 1564, the Spanish crown drafted him to help finish Magellans work.

Urdaneta served as pilot of a small fleet under the command of Miguel Lpez de Legazpi. The fleet, first following Magellans route westward from Mexico, captured the Philippines for Spain, and established Manila as a Spanish commercial base. In 1565, acting on local knowledge gleaned during his lengthy stranding on the Moluccas, he guided one ship, the San Pablo, north from Manila along the coast of Japan. There, he found the northward Kuroshio Current the first leg of a great watery highway that soon turned eastward, towards Mexico. This, at last, was the long-dreamed of tornaviaje, or return. Finding it was Urdanetas greatest accomplishment.

The narrow thread of force that connected Manila to Acapulco was, as it turns out, much less friendly to humans than its westward counterpart. The 11,500 miles Urdaneta crossed while returning to Mexico was then the longest sea journey ever made without landing. He took on no fresh water or food for more than four months. Much of the journey, as Careri would attest more than a century later, was both stormy and frigid. By the time they reached land again, Urdanetas crew was exhausted and malnourished. What they werent, mostly, was dead. In light of what followed, this is astounding.

One or two ships sailed Urdanetas route each year for the next two and a half centuries. The Manila Galleons were immensely profitable, with the lions share of the proceeds flowing to the Spanish colonists in Manila who financed and organised the trade. The ships arrived from Mexico laden with silver, which the Chinese badly needed for their rapidly expanding monetary system. They returned carrying not just Indonesian spice Spains original object but Chinese silk and porcelain, and Japanese jewels and preserves.

In Manila, life was leisurely, even beautiful. The work of administering the galleons took up only two or three months of a year, with the rest of the colonists time given purely to lavish parties, carriage rides, and social intrigue. The Spanish were singularly indolent occupiers, developing no aspect of the local economy except the galleon trade. They couldnt even be bothered to dig up the Philippines gold, currently calculated as the third largest reserve in the world. They were interested in profit, not in shaping the lives of the people they colonised.

Though just as one-dimensional as the conquer-and-plunder approach taken elsewhere by the Spanish, the Philippine occupation was different in one crucial way: the resource they were exploiting was not Manilas metal, spice or opium, but its location between the spice islands, China and the New World. Europe was still in the grip of a mercantilist economic ideology that valued exports over multilateral trade. But the galleons amazing profitability showed, long before Adam Smith wrote it down, that national specialisation was the source of wealth, and those who conquered the distance between regions could reap that wealth.

The galleons ushered in global capitalism in another, bleaker way. Friedrich Engels, observing the disease, malnourishment and suffering rampant in Londons nightmarish 19th-century slums, would write that everything which here arouses horror and indignation is of recent origin, belongs to the industrial epoch. Engels was wrong. The age of sail gave us the same kind of horror, or worse.

The crossing that Urdaneta first completed in four months took longer for the less savvy sailors who followed in his wake: five months, sometimes as many as eight, with no fresh water but from rain, and no fresh food but from the sea. Never before had humans been so isolated from their natural environment, for so long, in such numbers. Centuries before the slums of industrial Europe, the trade ships of the Pacific were full of sailors rolling in their own shit, starving to death, and ravaged by disease a Breugellian vista of Hell, compacted into a boat. At times, the dangers grew too great. In 1657, the San Jose was found drifting off the coast of Acapulco, every last crewman and passenger dead.

The typical provisions of a trading ship consisted of salted, preserved meat, a variety of beans, wine, oil and vinegar and, usually in scant portions, luxuries such as honey, chocolate, rice, almonds, and raisins. But the most famous staple was hardtack, or ships biscuit. This was a sort of primitive granola bar made by baking a dense dough until it was hard as a rock. The process was supposed to preserve it, but the sea was merciless. In every Mouthful, said Careri, There went down abundance of Maggots, and Gorgojas chewd and bruisd.

Gorgojo now means weevil, but there are multiple contemporary accounts of them feeding on crewmembers, so that meaning might have shifted. Regardless, various tiny creatures constantly besieged sailors veins and food supplies. Careri also describes soups swimming with worms of several sorts, and beans infested with maggots. The sailors had little option but to dig in.

Fishing provided psychological relief from this nightmare, but didnt solve the underlying, disastrous problem: the total lack of fruit and vegetables. A certain amount was loaded on departure from Manila, but this was reserved almost exclusively for officers, and consumed within weeks. Those aboard could not have understood the chemistry or biology that made this so deadly. They saw only the consequences.

At around the third month without landfall, the sailors gums would begin to swell, while their energy flagged. As their condition progressed, the gum tissue became so swollen that sailors sometimes cut large chunks from their own mouths and felt nothing. As lethargy overwhelmed them, the rest of their flesh began to decompose before their eyes, skin taking on the soft touch of fungus, and black ulcers swelling from it. This was followed by multiple organ failure and, ultimately, death.

Many between the 16th and 19th century reckoned scurvy a consequence of the malodorous vapours of the Pacific. Careri and many others knew that the best remedy against it, is going ashore but exactly why wasnt known. A scattered few had observed that fresh fruit cured the disease, but many seamen thought burying a victim up to the neck in dirt was also a powerful cure.

Even as their crews rotted alive, the galleons often carried Chinese ginger as part of their payload of prized spices. Though ginger was generally known for its medicinal as well as culinary properties, it was not understood that it is a source for ascorbic acid, or vitamin C, which is crucial to the bodys synthesis of collagen, the basic building block of our connective tissues and skin. In its absence, humans literally fall apart.

Those not killed by scurvy were at risk from another inescapable element of life on the galleons: severe crowding. Priests, who had free passage as missionaries, were sometimes crammed into cabins so small they had to rest their heads on one anothers feet. In 1767, aboard the San Carlos, 62 Jesuits were confined to a space meant for 20. They were then joined by 25 soldiers and a small herd of pigs. And these were the privileged: most sailors were expected to simply cram themselves into any available corner.

While all sea vessels are necessarily confined, the galleons had a particular problem. Space on these ships, especially on the return trip to Acapulco, was astronomically valuable. Their crowding embodied what the historian Jack Turner calls the law of increasing exoticism: The further they travelled from their origins, the more interesting [spices and trade goods] became, the greater the passions they aroused, the higher their value. The returns on even small cargos from the East could be huge.

This led to some amazingly inhumane decisions by those in charge. Careri describes huge shipboard cisterns, designed to both store and collect water on the journey, being smashed to make room for goods belonging to an officers friends. This was practically an act of murder: sailors ration of water was already a mere two pints a day. Frequently, ships sailed without backup sails and repair supplies, and it was common practice to store the guns to save space, making them useless for repelling pirates, which often lurked in wait of the galleons precious cargo.

The most common product of severe crowding was infectious disease. Microbiotic fiends traversed the constantly moist membranes of passengers and sailors, breeding typhus (known as ship fever) and typhoid (a disease spread by fleas and ticks). These were later joined by new diseases of exploration such as yellow fever and syphilis, the latter discovered in the New World before spreading to Europe and, primarily by the galleons themselves, to Asia.

Disease was exacerbated by a primitive view of cleanliness among Europeans of the age. Though latrines that cantilevered over the ocean were available on some galleons, many sailors didnt use them, instead shitting into the ships bilge, or even in the general hold. In part, Careri tells us, that was because of the incessant, brutal cold. But this indifference was widespread. The French sailor Franois Pyrard de Laval wrote in 1610 that typical Portuguese ships around India were mighty foul and stink withal; the most men not troubling themselves to go on deck for their necessities.

The lack of basic hygiene on ships illustrates the vast gap between early modern knowledge of geography and sailing on the one hand, and of the internal frontiers of the human body on the other. It was well-known that the world was round, part of the basis for the galleons amazing navigational leap. But few educated Europeans of the 16th and 17th century had more than the vaguest concepts of nutrition, infection, germs or the role of cleanliness in health. Most ships, even as late as the 18th century, relied for rudimentary medical help on a multitasking barber whose most effective tools were his enema syringe and tooth-puller.

This had deep intellectual roots. For the 15th and most of the 16th century, medical authorities were engaged in a kind of backwards march, blindly deferential to the second-century Greek physician Galen. Galenistic medicine was based on the theory of the humours, a set of materials with various qualities that had to be balanced within the body.

Advancement past this theory was hampered by a Papal ban on human dissection for research, not lifted until 1482. But a rationalistic approach to illness was, even then, centuries away. The Manila Galleons launched more than 30 years before the birth in 1596 of Ren Descartes, whose thinking would prove foundational for the very concept of an experiment. They launched precisely a century before Robert Boyle, in 1665, became the first to make biological use of the word cell. The connection between cleanliness and contagion wasnt persuasively argued until John Pringles Observations on the Diseases of the Army (1752). The first controlled experiments showing the effectiveness of citrus fruits in preventing scurvy were performed by James Lind in 1747. In fact, they were the first properly controlled medical experiments ever conducted.

But there was more than simple ignorance behind the suffering of the galleons sailors. The ships were often suspiciously overcrewed. They could be sailed by 40 or fewer, but carried crew complements of between 75 and, as the ships grew larger, 200. In Vanguard of Empire (1993), Roger C Smith points out that this overcrewing was due to the (correct) assumption that many of the crew would die.

Providing better food was known to decrease mortality emergency rations of higher quality were packed on all ships to aid the recovery of the ill (though Careri observed that most of that quickly ended up at the captains table). But providing higher quality food would have been a major expense for financiers, without greatly increasing the likelihood that a ships cargo would arrive intact which is all that really mattered to them. In fact, since the bulk of salaries was paid only at the end of a round trip, allowing half of all crew to die would have been a double cost saving. And so the sailors wore the yoke of global commerce, were worked to death, and then forgotten.

The Manila Galleon was ultimately undone by its own success. The route was eventually worked by ships of almost every European power, albeit illegally. Merchant competition for Asian goods drove up prices, while cheaper manufactured textiles undercut demand. In 1770, the Frenchman Pierre Poivre began successfully cultivating nutmeg and clove in the Indian Ocean, ending the spice monopoly of the Moluccas. The final decades of the Manila line were marked by frequent losses (both maritime and economic) and half-filled ships. The last galleon ran in 1815.

By then, it was just one part of an expansive network of global shipping. Commercial steam power, which emerged in 1807 on the Hudson River, would eventually make that trade faster, more efficient and much less deadly. The months-long Pacific crossing that killed a million men can now be made, even by the most leisurely of diesel container ships, in two weeks.

Reliable global trade underpins the unprecedented affluence now shared by many humans. In a better world, it might have spread its benefits even more widely. But todays robust network, and the technology that underpins it, would likely never have appeared without a template to guide their growth. That template was crude, exploitative, unreliable and very often, for the men whose bodies fuelled it, gruesomely lethal.

Read more from the original source:
Interstellar Trade - Atomic Rockets

Placenta | Amniotic tissue is not stem cell therapy – Dr …

There is a fascination among some patients with umbilical cord, amniotic fluid/membrane, and placenta membrane as a means of getting the best, or the most stem cells, in stem cell therapy treatment.

In the opinion of researchers cited in this article, that fascination and the supportive claims are unfounded. Further, the treatments mentioned and advertised in some doctors office as amniotic stem cell therapy is in fact not even stem cell therapy.

I am going to discuss amniotic stem cell therapy, which is in fact amniotic tissue treatment, placenta treatments and umbilical cord stem cell therapy in this article.

Marc Darrow MD, JD. Thank you for reading my article. You can ask me your questions about stem cell therapy using the contact form below.

The Interventional Orthopedics Foundation is a non-profit that provides CME-accredited courses that teach simple to advanced injection skills.

In a December 2015 press release, the Foundation issued a warning about faulty stem cell products after testing placental tissue-derived products. The warning: The products contained no live stem cells.

Here are the five key points published in that press release:

Every day here in Los Angeles, you can see advertisements for seminars and webinars for LIVE amniotic stem cell therapy. What do they base this on?

It is based on research saying one thing and amniotic stem cell therapy marketers saying another. Here is an example of one study:

On the release of a 2012 study examining the theory that Amniotic stem cells derived from donated amniotic fluid could be stored in banks, shipped to doctors and researchers, and used for various therapies, study author Dr. Pascale Guillot of the Department of Surgery and Cancer at Imperial College of London described amniotic stem cells this way:

Amniotic fluid stem cells are intermediate between embryonic stem cells and adult stem cells. They have some potential to develop into different cell types but they are not pluripotent.

Pluripotent cells can give rise to all of the cell types that make up the body. To make amniotic cells pluripotent they have to be genetically modified. Genetically modified stem cells are drugs and must be approved by the Food and Drug Administration (FDA).

Dr. Guillot and her research team in fact were trying to turn stem cells from amniotic fluid into pluripotent stem cells by way of culturing. The purpose was to get them to a point where they could replace embryonic stem cells for laboratory testing. That they succeeded lead some in the amniotic/stem cell therapy business to believe that donated amniotic stem cells, taken from a caesarian section delivery donor, could be persevered, freeze-dried, and then shipped out to doctors offices as stem cell therapy injections for osteoarthritis.

So as mentioned, this often cited 2012 study was not about joint degeneration but as Dr. Guillot pointed out . . . We are particularly interested in exploring their use in genetic diseases diagnosed early in life or other diseases such as cerebral palsy, and further replacing the need for embryonic stem cells. Of course embryonic stem cell research is fraught with ethical challenges and limited supply.

Dr Paolo De Coppi, from the UCL Institute of Child Health in London, who jointly led the study with Dr Guillot, said: This study confirms that amniotic fluid is a good source of stem cells. The advantages of generating pluripotent cells without any genetic manipulation make them more likely to be used for therapy.

Read again This study confirms that amniotic fluid is a good source of stem cells, BUT FOR research looking at genetic pediatric disorders and how these stem cells can be harvested and stored for future research for genetic engineering.

We are often asked if we can use stored cord blood in our treatments. Umbilical cord blood is different from bone marrow stems cells. Cord stem cells are hematopoietic stem cells (which can differentiate only into blood cells), and not pluripotent stem cells (such as stem cells from bone marrow, which can differentiate into any type of tissue).The research surrounding the use of Cord Blood centers around blood and immune diseases such as leukemia, certain cancers and anemia. Speculation that cord blood stem cells may help with brain trauma injuries, cognitive disorders, and autism is being tested in the medical research.

This is the gray line with Amniotic/Placenta stem cells.A company the markets amniotic stem cells as injections and as mail order service says this:Researchers have discovered that the amniotic fluid has an extremely high concentration of stem cells, even more than bone marrow in adults. When processed at an FDA regulated lab, the biologic material ends up containing significant regenerative properties, such as growth factors, hyaluronic acid and stem cell activators.

Now on the same website the treatment is called: Amniotic derived stem cell activator injections

There is no argument that amniotic fluid contains stem cells, perhaps more so than bone marrow derived stem cells, BUT, from placenta to your joint pain the stem cells get lost along the way.

By name they are something that activates stem cells. But how? According to the makers of oral supplements sold as stem cell activators, they are protein building blocks that rejuvenate aging stem cells by way of DNA telemore support. The claim is you may live longer.

In stem cell therapy, stem cell activators are the building block or the scaffold which the stem cells begin its repair.

We are going to examine a 2013 study produced by MiMedx Group, Inc., a company that describes itself as the global premier processor, marketer, and distributor of human amniotic tissue.This study was also produced in conjunction with the Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, the Georgia Institute of Technology. And the Angiogenesis Foundation. It was published in the International journal of wound healing.This is not a light-weight study.

Where are the stem cells in this study?

The researchers never say that the processed amniotic membrane have any. What they do say is that they stimulateHuman bone marrow mesenchymal stem cells already present in the body to multiple. (So does dextrose Prolotherapy and Platelet Rich Plasma).

Q. So what are stem cell activators? A. They are growth factors that help your own bone marrow mesenchymal stem cells multiply.

Q. So where are the amniotic stem cells? A. There are none

Researchers have discovered that the amniotic fluid has an extremely high concentration of stem cells, even more than bone marrow in adults. When processed at an FDA regulated lab, the biologic material ends up containing significant regenerative properties, such as growth factors, hyaluronic acid and stem cell activators. They do not survive the processing, only the remnants of their ability to activate bone marrow stem cells.

But isnt this still a great selling point for amniotic stem cell activator therapy?

No because there is already a well proven stem cell activator that works well and is a fraction of the cost, Platelet Rich Rich Plasma and dextrose prolotherapy.

Doctors from George Washington University and the University of Southern California went into this question with an open mind. Lets point out that we are NOT talking about stem cell therapy we are talking about placenta tissue preparation.

Here is what their study suggests: A review of the small number of reported studies revealed a high degree of variability in placental cell types, placental tissue preparation, routes of administration, and treatment regimens, which prohibits making any definitive conclusions. Currently, the clinical use of placenta is limited to only commercial placental tissue allografts, as there are no placenta-derived biological drugs approved for the treatment of orthopaedic sports medicine conditions in the United States.1

This April 2017 study is not very robust in its clinical recommendations.

So where did all this hype come from?

Doctors at Rush University School of Medicine wrote this in 2016 in the American journal of sports medicine:

Alter their biological properties?

With these type of research I would find it difficult to convince my patients, who are always eager for research to support their decision to undergo our treatments that the scientific community is as excited about amniotic/placenta stem cells as a potential help for their osteoarthritis.

1 McIntyre JA, Jones IA, Danilkovich A, Vangsness Jr CT. The Placenta: Applications in Orthopaedic Sports Medicine. The American Journal of Sports Medicine. 2017 Apr 1:0363546517697682.

2 Riboh JC, Saltzman BM, Yanke AB, Cole BJ. Human Amniotic MembraneDerived Products in Sports Medicine: Basic Science, Early Results, and Potential Clinical Applications. The American journal of sports medicine. 2016 Sep;44(9):2425-34.

Excerpt from:
Placenta | Amniotic tissue is not stem cell therapy - Dr ...

Oregon Regenerative Stem Cell Medical Center: Regenerative …

At Oregon Regenerative Stem Cell Medical Center in Wilsonville, Oregon, Amicia Bullard, PA and her friendly staff use the most effective, noninvasive treatments to alleviate aches, pains, and stiffness in joints, muscles, ligaments, and tendons. If you or a loved one suffers from constant or episodic pain, the support and care you need are available.

Regenerative medicine treatment plans focus on reducing pain and inflammation, optimizing healing for a quicker recovery, and improving mobility and flexibility without the burden of prescription medication or invasive surgery.

Amicia Bullard and her compassionate and knowledgeable staff treat several conditions caused by injuries, aging, or congenital conditions by combining innovative stem cell and platelet rich plasma (PRP) therapies with traditional anesthetic and corticosteroid treatments.

The journey to healing starts with a personalized consultation to determine which combination of therapies is best for your case. Because being overweight can exacerbate many musculoskeletal conditions, Oregon Regenerative Stem Cell Medical Center provides medical weight loss to improve outcomes, as well.

The ultimate goal for every team member at Oregon Regenerative Stem Cell Medical Center is helping women, men, and children alleviate pain by promoting the body to regenerate tissue and heal itself. Return to an active, pain-free lifestyle by scheduling an appointment over the phone or online today.

Read more here:
Oregon Regenerative Stem Cell Medical Center: Regenerative ...

Illinois Stem Cell Clinic – Illinois Stem Cell Clinic …

Umbilical cord cells include stem cells, growth factors and a range of other beneficial proteins and compounds. We use blood from the umbilical cord which has been purified to get rid of any harmful substances that might cause rejection of the treatment by your body. We inject the treated cord blood into the affected area, where the various active compounds found in cord cells go to work immediately to begin inflammation reduction and the promotion of healthy cell division and renewal. Some of the active compounds at work include VEGF (Vascular Endothelial Growth Factor), IL-LRA (Interleukin-1, a receptor antagonist, stem cell factors (SCF), FGF-2 (Fibroblast Growth Factor-2) and Transforming Growth Factor-beta (TGF-beta). Each of these compounds has a slightly different effect, but the net result is that the damaged cells in your joints are given the ingredients they need to kick-start healthy renewal and regeneration. The injection changes the chemistry inside the joint, creating a healthier environment that encourages positive, healing changes to take place. A better blood supply to the area, a reduction in damaging chronic inflammation and stimulation of healthy tissue growth are all typical consequences of the minimally invasive stem cell treatments we provide. By using umbilical cord cells in this way, its possible to transform joint therapy into a holistic healing process that prompts the body to enhance its own regenerative efforts. This results in a natural process of joint health improvement in the weeks or months following the injection.

Read the rest here:
Illinois Stem Cell Clinic - Illinois Stem Cell Clinic ...

Adoptive T Cell Therapy 2: Development

Cambridge Healthtech Institutes 5th Annual August 30-31, 2018

In 2017, two CAR T cell therapies were approved by the Food and Drug Administration (FDA). With multiple engineered receptors making preclinical impact, many biotech and pharma companies are already entering other clinical trials in a race to get to market. Has this promising field finally reached a tipping point? Technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management remain. Cambridge Healthtech Institutes 5th Annual Adoptive T Cell Therapy 2: Development conference focuses on the steps needed to deliver CAR, TCR, NK, and TIL therapies to the clinic. Overall, this event addresses clinical progress, case studies, and the critical components for making adoptive T cell therapy work.

Final Agenda

Day 1 | Day 2 | Download Brochure Speaker Biographies | Participating Companies | Emerging Company Showcase Presenters

THURSDAY, August 30

7:45 am Registration & Morning Coffee (Harbor Level)

8:25 Chairpersons Opening Remarks

Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies

8:30 FEATURED PRESENTATION: A Translational Perspective of Development of Yescarta (Axicabtagene Ciloleucel), a First-in-Class CAR T Cell Product for Diffuse Large B Cell Lymphoma

Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company

Yescarta (Axicabtagene Ciloleucel) is an anti-CD19 CAR T cell therapy that received approval for treatment of relapsing or refractory DLBCL. This presentation describes key elements of the translational program, correlates of toxicities and durable objective response, product characteristics, patient conditioning, and importance of tumor microenvironment. It also showcases major lessons learned and challenges in developing cell-based immunotherapies.

9:00 NEW: Selected Poster Presentation: TAC-T, A Novel T Cell Therapy, Co-Opts the Endogenous T Cell Receptor for Effective, Safe, and Persistent Tumor Rejection

Christopher W. Helsen, PhD, Director, R&D and Head, Platform Development, Triumvira Immunologics, Inc.

9:30 Predictors of Response to CD19-Specific CAR T Therapy in B-CLL

Jun Xu, PhD, Associate Director, Product Development Laboratory, Center for Advanced Cellular Therapeutics, Perelman Center for Advanced Medicine, University of Pennsylvania

To date, it has not been possible to identify patient- or disease-specific factors that predict why some B-CLL patients and not others have such dramatic responses to CAR T cell treatment. We explored the mechanisms associated with clinical response and lack of response to CAR T therapy, providing evidence for intrinsic T cell fitness in mediating durable anti-tumor responses and long-term complete remissions.

10:00 Coffee Break in the Exhibit Hall (Last Chance for Poster Viewing) (Commonwealth Hall)

10:45 Facing the Challenges of Apheresis Network Management

Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies

For companies working in cell therapies, managing and maintaining your apheresis (cell collection) network is a critical challenge. How do you know which center is best equipped to handle your needs? How do you evaluate their compliance with FDA and international regulations? Hines discusses the key questions to ask and gives you the tools youll need to evaluate centers, secure your supply chain and advance your cell therapy program.

11:15 Solving the Challenges of Large-Scale GMP T Cell Manufacturing

Steven L. Highfill, PhD, Assistant Director, Product Development and Management, Center for Cellular Engineering, Clinical Center, National Institutes of Health

This presentation covers current, ongoing GMP manufacturing efforts at the NIH. Highlights focus on CAR T cell manufacturing and some of the challenges that we had to overcome specifically when using autologous patient-derived starting material. In addition, I discuss some newer closed-system manufacturing platforms that will make it easier for academic institutes to provide cell therapy options to their patients.

11:45 Sponsored Presentation (Opportunity Available)

12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:45 Session Break

1:40 Chairpersons Remarks

Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company

1:45 FEATURED PRESENTATION: Stress-Resistant T Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, FACS, FCCP, Associate Attending and Deputy Chief, Thoracic Surgery; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; Director, Mesothelioma Program, Memorial Sloan Kettering Cancer Center

CAR T cell therapy efficacy in solid tumors is limited by PD-1/PD-L1 pathway. We have shown that exhausted CAR T cells can be rescued by anti-PD1 agents or by a decoy receptor, PD-1 dominant negative receptor cotransduced with CAR T cells to promote functional persistence. The presentation focuses on cell-intrinsic and extrinsic methods in overcoming checkpoint blockade in cellular immunotherapy.

2:15 TRAP CAR T & Related Cell Therapies: Can Local Delivery Solve Efficacy and Safety Challenges in Solid Tumor Immuno-Oncology?

Janet R. Rea, MSPH, RAC, Senior Vice President, Regulatory, Quality & Clinical Affairs, Atossa Genetics

This presentation reviews cell therapy evolution and challenges. It includes considerations of local delivery options using breast cancer as a model.

2:45 Selected Poster Presentation: Phase I Study of an Adoptive Cellular Immunotherapy by Silencing cbl-b in Autologous Peripheral Blood Mononuclear Cells

Kathrin Thell, PhD, MSc, In Vivo Scientist, Apeiron Biologics AG

3:15 Refreshment Break (Commonwealth Hall)

3:45 Eutilexs 4-1BB CTL Adoptive T Cell Therapy: Clinically Safe and First Efficacy in Solid Tumors

Agustin de la Calle, PhD, CBO, Eutilex Co., Ltd.

Eutilexs 4-1BB CTL therapy is the autologous T cell therapy proven safe in man without treatment-related toxicity and no CRS. Efficacy in hematological cancers and solid tumors: brain, breast, lung, tracheal, pancreatic cancers, CRC and melanoma. Complete remissions were observed in Hodgkins and NK/T cell lymphomas. Phase I safety accepted single dose in terminal patients but relapsed patients became responsive again to further treatments. Leader in COGS: simple outpatient procedure.

4:15 Engineering NK Cells for Enhanced Potency and Persistence

James B. Trager, PhD, Senior Vice President, R&D, Nkarta, Inc.

NK cells form a first line of defense against cancer, and they can be formidable mediators of cytotoxicity and adaptive immunity. Efforts to maximize their potential as cancer therapeutics are hampered by difficulty in expanding NK cells, relatively short in vivo persistence, and the ability of tumor cells to evade NK recognition. We discuss recent progress in overcoming these barriers to successful therapeutic application of NK cells.

4:45 FEATURED PRESENTATION: Tricked-Out CARs: Next-Generation Approaches to Enhance and Optimize CAR T Cell Function

Benjamin Boyerinas, PhD, Senior Scientist, Immunotherapy, bluebird bio

Genetically engineered CAR T cells can be further engineered to survive and overcome immune evasion mechanisms employed by tumors. We have been developing a novel TGF- signal conversion platform that provides a T cell supportive signal upon exposure to TGF- within the hostile tumor microenvironment. This approach, combined with other methodologies such as gene editing and drug-regulated activation, have the potential to enhance specific activity within solid tumors.

5:15 End of Day

Day 1 | Day 2 | Download Brochure

FRIDAY, August 31

7:45 am Registration (Plaza Level)

8:00 Breakout Discussion Groups with Continental Breakfast (Beacon Hill)

This session features discussion groups that are led by a moderator who ensures focused conversations around the key issues listed. Attendees choose to join a specific group, and the small, informal setting facilitates sharing of ideas and active networking. Details on the topics and moderators are available on the conference website.

9:00 Chairpersons Remarks

Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics, Inc.

9:05 GOLD: Activation-Induced Payload Delivery for T Cell Therapies

Gus Zeiner, PhD, CSO, Chimera Bioengineering

GOLD is an endogenous post-transcriptional gene regulatory node that couples T cell metabolic states to transgenic payload outputs. Conditional payload expression is induced by signaling through either the native T cell receptor or a CAR. GOLD is payload-agnostic, and enforces low basal payload expression in resting T cells with a wide dynamic range in activated T cells. GOLD-mediated regulation is non-immunogenic, making GOLD-enabled T cell therapeutics compatible with long-term persistence.

9:35 Developing Tumor Infiltrating Lymphocytes for the Treatment of Cancer

Maria Fardis, PhD, President & CEO, Iovance Biotherapeutics

Recent FDA approvals of Kymriah and Yescarta show that cell therapies are viable options for treatment of hematological malignancies. Incidence of solid tumors are, however, approximately 10 times higher than hematological malignancies. Available therapies for solid tumors include chemotherapy, radiotherapy, and immunotherapy. Immunotherapies, such as Anti-PD-1 antibodies, have shown promise, but in many cases, although the overall response rate is not high, discontinuation due to adverse events remains an issue. Iovance is developing -infiltrating lymphocytes (TIL), a one-time cell therapy treatment that leverages and enhances the bodys natural defenses against certain aggressive solid tumors. TIL is currently under investigation in several multi-center Phase II clinical trials and preliminary results have demonstrated safety and efficacy in melanoma, head and neck and cervical cancer patients with multiple prior therapies which constitutes unmet medical need.

10:05 PM21-NK Cells for Cancer Therapy

Robert Igarashi, PhD, President, CytoSen Therapeutics

CytoSen is advancing NK cell therapy for treatment of cancer. CytoSens methods for stimulating NK cells with membrane bound (IL21), originally developed by Dr. Dean A. Lee, produces NK cells with high anti-tumor potency and can generate the highest doses. We plan to leverage our particle-based platform, that has logistical advantages, to pursue clinical studies in leukemia.

10:35 Coffee Break (Plaza Level)

11:00 A TCR-Based Chimeric Antigen Receptor

Even Walseng, PhD, Staff Scientist, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health; Department of Immunology, Hospital Radiumhospitalet, Institute for Cancer Research, University of Oslo

Although CARs are very potent, the recognition is limited to membrane antigens which represent around 1% of the total proteins expressed, whereas TCRs have the advantage of targeting any peptide resulting from cellular protein degradation. To expand the horizon of TCR use, we have successfully fused a soluble TCR construct to a CAR-signaling tail. We demonstrate that the TCR-CAR redirection is not restricted to T cells and hence opens therapeutic avenues combing the killing efficiency of NK cells with the diversified target recognition of TCRs.

11:30 Hijacking CAR19 T Cells to Address Critical Issues in Cell Therapy: Application to Diverse Indications

Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics, Inc.

The Aleta platform addresses critical issues in cell therapy including CAR persistence, antigen escape and antigen heterogeneity, and provides important solutions for treating both hematologic and solid tumors. The key element of our technology is the use of novel fusion proteins to redirect CAR T specificity. Our lead programs are directed to B cell malignancies, AML and solid tumors.

12:00 Close of Adoptive T Cell Therapy 2: Development

Day 1 | Day 2 | Download Brochure Speaker Biographies | Participating Companies | Emerging Company Showcase Presenters

Follow this link:
Adoptive T Cell Therapy 2: Development

Chimeric Antigen Receptor (CAR) T-Cell Therapy | Leukemia …

Possible Side Effects of CAR T-Cell Therapy

Cytokine-ReleaseSyndrome (CRS). This potentially seriousside effectis frequently associated with CAR T-cell therapy. Cytokines (chemical messengers that help the T cells carry out their functions) are produced when the CAR T cells multiple in the body and kill the cancer cells. CRS symptoms can range from mild flulike symptoms that include nausea, fatigue, headache, chills and fever to more serious symptoms, such as a low blood pressure, tachycardia (abnormally rapid heart rate), capillary leakage (fluid and proteins leak out of tiny blood vessels and flow into surrounding tissues, resulting in dangerously low blood pressure), cardiac arrest, cardiac arrhythmias, cardiac failure, hemophagocytic lymphohistiocytosis (life-threatening immunodeficiency)/macrophage activation syndrome (life-threatening complication of rheumatic disease) (HLH/MAS), hypoxia (lack of oxygen reaching the tissue), renal insufficiency (poor function of the kidneys), poor lung oxygenation and multiple organ failure. Severe CRS requires intensive care treatment. Some patients may also experience neurological symptoms (see Neurologic Toxicities, below). Although most symptoms are reversible, the potential life-threatening risk of CAR T-cell therapy should not be underestimated. Deaths have been reported in CAR-T cell trials.

Depending on the patient and the CAR T cells, CRS may occur within 1 to 21 days of CAR T-cell infusion. The duration of CRS is variable and it depends on the type of intervention used to manage it, typically resolving within 1 to 2 weeks after CAR T-cell infusion.

Neurologic Toxicities. The frequency, severity and nature of neurological effects appear different between CAR-T products. Common symptoms include language impairment (aphasia), confusion, delirium, involuntary muscle twitching, hallucinations, or unresponsiveness. Seizures have also been reported.

Neurotoxicity has been reversible in most cases and the symptoms have resolved over several days without intervention or apparent long-term effects. However there can be life-threatening adverse neurological events. The cause of neurotoxicity is the subject of intense investigation by researchers.

B-CellAplasia.CAR T-cell therapy targeting antigens found on the surface of B cells not only destroys cancerous B cells but also normal B cells. Therefore, B cell aplasia (low numbers of B cells or absent B cells) is an expected result of successful CD19-specific CAR T-cell treatment and has served as a useful indicator of ongoing CAR T-cell activity. This effect results in less ability to make the antibodies that protect against infection. Intravenous or subcutaneous immunoglobulin replacement therapy may be given with the aim of preventing infection. Long-term follow-up study is needed to assess the late effects of B-cell aplasia.

TumorLysisSyndrome (TLS).Another known side effect of CAR T-cell therapy is tumor lysis syndrome (TLS), a group of metabolic complications that can occur due to the breakdown of dying cellsusually at the onset of toxic cancer treatments. However, TLS can be delayed and may occur one month or more after CAR T-cell therapy. TLS can cause organ damage and can be a life-threatening complication of any treatment that causes breakdown of cancer cells, including CAR T cells. The complication has been managed by standard supportive therapy.

Anaphylaxis (Life-threatening Allergic Reaction). There is potential for a patient receiving CAR T-cell therapy to have an overwhelming immune response against the CAR itself, called anaphylaxis. Symptoms associated with anaphylaxis include hives, facial swelling, low blood pressure and respiratory distress. There have been a few reports of acute anaphylaxis. Thorough monitoring and immediate treatment of this life-threatening side effect are critical for patients receiving CAR T-cell therapy.

Early outcomes from CAR T-cell trials have generated impressive results in patients with blood cancers.

Acutelymphoblasticleukemia (ALL).).With the FDA approval of tisagenlecleucel (KymriahTM), CAR T-cell therapy represents an option for B-cell acute lymphoblastic leukemia (B-ALL) patients who have relapsed after intensive chemotherapy or a stem cell transplant. In some studies, up to 90 percent of children and adults with B-cell acute lymphoblastic leukemia who had either relapsed multiple times, or failed to respond to standard therapies, achieved remission after receiving CAR T-cell therapy. Relapses may be due to the tumor cells losing the expression of the CD19 antigen, to the limited persistence of CAR T-cells, or inhibition of CAR T-cell activity.

Other blood cancers.Studies of CAR T-cell therapy in other blood cancers, including chronic lymphocytic leukemia (CLL), as well as multiple myeloma, also show potential. Research is also under way, exploring the application of CAR T-cell therapy in the treatment of solid tumors.

While data is fast emerging as to the early responses to CAR T-cell therapy, most of the patients participating in these clinical trials have only been followed for a relatively short time. Following these trial participants over the long term will provide information as to the length of their responses. It is important for more pediatric and adult patients to be enrolled in clinical trials. Larger study samples, evaluated over more extended periods, will help researchers further understand the impact of this type of therapy, ways to reduce its toxicity and improve the management of adverse side effects.

Visit link:
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Leukemia ...